<DOC>
	<DOCNO>NCT01172652</DOCNO>
	<brief_summary>The specific aim study evaluate efficacy , tolerability , safety ziprasidone monotherapy comparison placebo treatment ambulatory bipolar disorder co-morbid lifetime panic disorder generalize anxiety disorder current least moderately severe anxiety .</brief_summary>
	<brief_title>Ziprasidone Bipolar Disorder With Comorbid Lifetime Panic Generalized Anxiety Disorder ( GAD )</brief_title>
	<detailed_description>This randomize , double-blind , placebo control , parallel-group , 8-week trial ziprasidone compare placebo outpatient subject lifetime bipolar I , II , NOS disorder , lifetime panic generalize anxiety disorder , current diagnosis least moderately severe anxiety symptom . Approximately 50 subject randomize . Subjects randomize ziprasidone placebo 1:1 ratio . No concomitant psychotropic medication allow throughout study except prn lorazepam first two week management affective anxiety symptom , prn zolpidem zaleplon management insomnia benztropine management EPS . Throughout study , psychiatric scale use assess psychiatric symptom presence treatment-emergent adverse event monitor record .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Subjects must least age 18 year age old 65 . Subjects must lifetime bipolar I , II , NOS disorder define DSMIV TR criterion ( 26 ) . Subjects must lifetime panic disorder generalize anxiety disorder ( GAD ) define DSMIV criterion ( except clause `` occur exclusively mood disorder '' Criterion F GAD ) . Subjects ' bipolar symptom must moderate severity , define CGIBP &lt; 4 ( 27 ) . Subjects ' anxiety symptom must least moderate severity , define CGIS &gt; 4 ( 28 ) . Subjects must receive regular mood stabilizing , antidepressant , antipsychotic , anxiolytic medication least one week prior baseline . Patients receive fluoxetine depot antipsychotic medication least four week prior baseline . Subjects legally authorize representative must sign Informed Consent Document nature trial fully explain . If female , subject must : postmenopausal , surgically incapable childbearing , practice medically acceptable effective method ( ) contraception ( e.g. , hormonal method , barrier method , intrauterine device ) least one month prior study entry throughout study . Subjects lifetime bipolar disorder DSMIVTR criterion ( 26 ) . Subjects lifetime panic disorder generalize anxiety disorder DSMIVTR criterion ( 26 ) . Subjects receive treatment antimanic mood stabilize medication ( lithium , valproate , carbamazepine , antipsychotic ) , investigator ' judgment , require ongoing treatment medication . Subjects whose bipolar symptom presently moderately severe ( CGIBP &gt; 5 ) ( 27 ) . Subjects whose anxiety symptoms presently less moderately severe ( CGIS &lt; 3 ) ( 28 ) . Subjects clinically significant suicidal homicidal ideation . Subjects current DSMIV TR Axis I diagnosis delirium , dementia , amnesia , cognitive disorder ; DSMIV TR diagnosis substance dependence disorder within past six month ; lifetime DSMIV TR psychotic disorder ( e.g. , schizophrenia schizoaffective disorder ) . Subjects serious general medical illness include hepatic , renal , respiratory , cardiovascular , endocrine , neurological , hematological disease determine clinical judgment clinical investigator . Subjects hypo hyperthyroidism unless stabilize thyroid replacement &gt; 3 month . Subjects clinically significant abnormality prestudy physical exam , vital sign , EKG , laboratory test . Subjects allergic demonstrate hypersensitivity intolerance ziprasidone . Women pregnant nursing . Subjects received experimental drug use experimental device within 30 day . Subjects history neuroleptic malignant syndrome . A patient diabetes mellitus ( DM ) fulfil one follow criterion : Unstable DM define enrollment glycosylated hemoglobin ( HbAlc ) &gt; 8.5 % Admitted hospital treatment DM DM relate illness within past 12 week Not physician care DM Physician responsible patient 's DM care indicate patient 's DM control Physician responsible patient 's DM care approve patient 's participation study Has dose oral hypoglycemic drug ( ) and/or diet 4 week randomization . For thiazolidinediones ( glitazones ) period le 8 week randomization . Taking insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week Note : If patient DM meet one criterion , patient exclude even treat physician believe patient stable participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Bipolar disorder</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Panic</keyword>
	<keyword>GAD</keyword>
	<keyword>Generalized Anxiety Disorder</keyword>
</DOC>